BACK

Mark Simon

Mark Simon

Co-Founder and Advisor

New York Office  |  mark.simon@torreya.com   |   212.257.5809

Mark Simon, Torreya Co-Founder and Advisor, has 30 plus years experience advising biotech and specialty pharma companies. He has worked on more than 175 financing and M&A transactions totaling over $50 billion in value.

Before co-founding Torreya in 2007, Mark was a Managing Director and the Head of Life Sciences Investment Banking at Citigroup, where he covered global pharmaceutical companies, with a focus on large-capitalization players in the US, Europe, and Japan. Prior to his tenure at Citigroup, Mark served as a Managing Director at Robertson Stephens in San Francisco and New York. There, he was involved in raising 45% of all biotech dollars raised in the US from 1999-2001.

Before moving into Investment Banking, Mark was a senior biotech research analyst at Robertson Stephens, where he was named Wall Street All-Star Analyst three years in a row. He began his career as a research associate at Kidder Peabody in New York in 1984, covering biotechnology and health care services companies.

Mark holds a B.A. in history from Columbia College and an M.B.A. from Harvard Business School.

He serves on several boards of philanthropic organizations and for-profit companies.

Selected Transactions

Saama Technologies
Financing with
Perceptive Advisors
$40 Million
March 2019
Kineta
Research collaboration and license agreement for
RIG-I pathway with
Pfizer
Up to $505 million
December 2018
Mallinckrodt Pharmaceuticals
Sale of
Intrathecal business to
Piramal
$203 million
March 2017
Phenex
Sale of FXR program to
Gilead
Up to $470 million
January 2015
Chelsea Therapeutics
Sale to
Lundbeck
$658 million
June 2014
Xoma
Acquires royalty interest position for 7 assets from
Agenus
$15 million
September 2018
EyePoint Pharmaceuticals
Debt financing for acquisition of Icon Biosciences from
SWK Holdings
$20 Million
March 2018
XOMA
License of
Gevokizumab and
certain associated IP to
Novartis
$31 million upfront
August 2017
Essential Pharmaceuticals
Asset sale to
Accord
Undisclosed
July 2017
Assembly Biosciences
Microbiome partnership with
Allergan
$2.6 billion
($50 million upfront)
January 2017
XOMA
Sale of royalties to
Healthcare Royalty Partners
$22 million
December 2016
PhosImmune
Sale to
Agenus
Up to $45 million
($16 million upfront)
December 2015
XOMA
Sale of
biologics manufacturing
facilities to
Agenus
$5 million in cash +
$1 million in stock
November 2015
XOMA
License of global rights
for Anti-TGF-beta
antibody program to
Novartis
Up to $517 million
October 2015
cCam Biotherapeutics
Sale to
Merck
Up to $605 million
July 2015
PDI
Acquisition of
Redpath Integrated Pathology
Up to $35 million
October 2014
CureTech
License of Pidilizumab to
Medivation
Up to $335 million
with royalty
October 2014
Compugen
Financial advisor on
follow-on offering
Undisclosed
$72.5 million
February 2014
4-Antibody AG
Sale to
Agenus
$40+ million with
$10 million upfront
January 2014
Pinnacle Biologics
Sale to
Concordia Healthcare
Undisclosed
December 2013
Correvio
Sale to
Cardiome
19.9% of shares +
$12 million
November 2013
Compugen
Advisor on oncology partnership with
Bayer
$550 million with
$10 million upfront
August 2013
Molecular Insight
Sale for up to
$106 million to
Progenics
$12 million +
milestones
January 2013
GTx
Sale of Fareston® to
Prostrakan/Kyowa Hakko Kirin
$21.7 million
October 2012
Xanodyne
Sale of
Amicar® rights to
Versapharm
Undisclosed
August 2012
Xanodyne
Sale of
Roxicodone® to
Covidien
Undisclosed
August 2012
Xanodyne
Sale of Zipsor® to
Depomed
Undisclosed
June 2012
Xanodyne
Co-promotion for
Zipsor®
Medimetriks
Undisclosed
May 2011
GTCR
Advisor in the acquisition of six products from
UCB
Undisclosed
July 2010
Shareholder Group
Advisor to Genentech
major shareholder
in sale to
Roche
$46 billion
March 2009
ProEthic Pharma
Sale to
Kowa Pharmaceuticals
Undisclosed
April 2008